TP53 and hepatocellular carcinoma: To characterize heterogeneity in HCC TIS and to explore exposure of shared actionable vulnerabilities, we initially characterized the effects of three TIS inducers – alisertib (an Aurora kinase A inhibitor), etoposide (a topoisomerase II inhibitor), and CX5461, an RNA polymerase I inhibitor – on well-established HCC cell lines with different p53 mutational status, systematically comparing changes in transcription and intracellular innate pathways, SASP characteristics and the senescence-associated surfaceome (SASome).